Oncimmune Holdings (LSE:ONC) Debt-to-Equity : -4.12 (As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Debt-to-Equity?

Oncimmune Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was £0.98 Mil. Oncimmune Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was £4.28 Mil. Oncimmune Holdings's Total Stockholders Equity for the quarter that ended in Feb. 2024 was £-1.28 Mil. Oncimmune Holdings's debt to equity for the quarter that ended in Feb. 2024 was -4.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oncimmune Holdings's Debt-to-Equity or its related term are showing as below:

LSE:ONC' s Debt-to-Equity Range Over the Past 10 Years
Min: -42.66 Med: -0.47 Max: 8.07
Current: -4.12

During the past 12 years, the highest Debt-to-Equity Ratio of Oncimmune Holdings was 8.07. The lowest was -42.66. And the median was -0.47.

LSE:ONC's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs LSE:ONC: -4.12

Oncimmune Holdings Debt-to-Equity Historical Data

The historical data trend for Oncimmune Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Debt-to-Equity Chart

Oncimmune Holdings Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

Aug23

Debt-to-Equity

Get a 7-Day Free Trial

-42.66

1.81

-3.92

8.07

Oncimmune Holdings Semi-Annual Data
	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Nov19	May20	Nov20	May21	Nov21	May22	Feb23	Aug23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															6.78	-3.92	-1.72	8.07	-4.12

Competitive Comparison of Oncimmune Holdings's Debt-to-Equity

For the Biotechnology subindustry, Oncimmune Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncimmune Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Debt-to-Equity falls into.

Oncimmune Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oncimmune Holdings's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.332	+	4.969)	/	0.657
	=	8.07

Oncimmune Holdings's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.984	+	4.278)	/	-1.277
	=	-4.12

Oncimmune Holdings (LSE:ONC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oncimmune Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncimmune Holdings (LSE:ONC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OCY:Germany

Address

1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB

Website

https://www.oncimmune.com

Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines